Position in ABBV
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$20,886
+$2,835 QoQ
Shares Held
83
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#4,110
of 4,153 holders
Holding Since
Jun 2023
13 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Robinswood Financial LLC holds $915,768 across 12 Drug Manufacturers - General names. ABBV ranks #6 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
2,035 | $516,828 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,059 | $136,081 | |
| 3 | LLY |
ELI LILLY & Co
|
81 | $97,153 | |
| 4 | PFE |
Pfizer Inc
|
1,524 | $36,697 | |
| 5 | AMGN |
Amgen Inc
|
100 | $36,212 | |
| 6 | ABBV |
AbbVie Inc.
This page
|
83 | $20,886 | |
| 7 | AZN |
Astrazeneca PLC
|
109 | $20,668 | |
| 8 | SNY |
Sanofi
|
432 | $18,429 |
All Filings in ABBV
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,886 | 83 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $18,051 | 83 | Shares | Sole | 2026-07-13 | |
| 2025-12-31 | $8,225 | 36 | Shares | Sole | 2026-07-14 | |
| 2025-09-30 | $8,335 | 36 | Shares | Sole | 2026-07-14 | |
| 2025-06-30 | $6,682 | 36 | Shares | Sole | 2026-07-14 | |
| 2025-03-31 | $7,542 | 36 | Shares | Sole | 2026-07-14 | |
| 2024-12-31 | $6,397 | 36 | Shares | Sole | 2026-07-15 | |
| 2024-09-30 | $7,109 | 36 | Shares | Sole | 2026-07-15 | |
| 2024-06-30 | $6,174 | 36 | Shares | Sole | 2026-07-15 | |
| 2024-03-31 | $6,555 | 36 | Shares | Sole | 2026-07-15 | |
| 2023-12-31 | $5,578 | 36 | Shares | Sole | 2026-07-15 | |
| 2023-09-30 | $5,366 | 36 | Shares | Sole | 2026-07-15 | |
| 2023-06-30 | $4,850 | 36 | Shares | Sole | 2026-07-14 | |
| No filing history on record for this holder in this stock. | ||||||